SearchDictionaryMobileLogin

L Klareskog Selected Research

Necrosis

11/2005Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
10/2005Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
11/2004Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
09/2004Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
12/2003Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
06/2003Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
05/2002Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
01/2002Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families.

Articles by Research Topic

Disease

21Rheumatoid Arthritis
10/2008 - 01/2000
8Necrosis
11/2005 - 01/2002
3Experimental Arthritis
03/2005 - 09/2002
2Inflammation
09/2007 - 09/2002
2Arthritis (Polyarthritis)
01/2007 - 10/2001
2Rheumatic Diseases (Rheumatism)
11/2005 - 11/2004
1Lymphoma (Lymphomas)
12/2005
1Neoplasms (Cancer)
10/2005
1Lupus Nephritis
01/2004
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2002
1Myositis (Idiopathic Inflammatory Myopathies)
10/2001
1Mixed Connective Tissue Disease (MCTD)
05/2000
1CREST Syndrome (Syndrome, CREST)
05/2000

Drug/Important Bio-Agent (IBA)

7TNFR-Fc fusion protein (etanercept)FDA Link
10/2008 - 05/2002
4Methotrexate (Mexate)FDA LinkGeneric
10/2008 - 08/2005
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2005 - 11/2000
2rituximab (Mabthera)FDA Link
02/2007 - 01/2004
2TEMPOIBA
03/2006 - 08/2005
2Interleukin-1 (Interleukin 1)IBA
11/2005 - 11/2004
2CytokinesIBA
03/2005 - 06/2000
2AntigensIBA
10/2001 - 02/2001
2Collagen Type II (Type II Collagen)IBA
02/2001 - 01/2000
1Prednisolone (Predate)FDA LinkGeneric
09/2007
1Antirheumatic Agents (DMARD)IBA
12/2006
1SteroidsIBA
12/2005
1Anti-Idiotypic AntibodiesIBA
12/2005
1Silicon Dioxide (Sand)IBA
04/2005
1CNI 1493IBA
03/2005
1Anticardiolipin AntibodiesIBA
09/2004
1prostaglandin-E synthaseIBA
06/2004
1cobalt mesoporphyrin (CoMP)IBA
04/2004
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2004
1infliximab (Remicade)FDA Link
12/2003
1Genetic Markers (Genetic Marker)IBA
06/2003
1Hyaluronic Acid (Hyaluronan)IBA
09/2002
1Fibrinogen (Factor I)IBA
09/2002
1cartilage matrix proteinIBA
09/2002
1Interleukin-10 (Interleukin 10)IBA
01/2002
1Histocompatibility Antigens Class IIIBA
10/2001
1AntibodiesIBA
10/2001
1Glutens (Glutelin)IBA
10/2001
1AutoantibodiesIBA
05/2000
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
04/2000
1Interferon-gamma (Interferon, gamma)IBA
01/2000
1HLA-DQ8 antigenIBA
01/2000
1HLA-DRB1 antigen (HLA DRB1)IBA
01/2000

Therapy/Procedure

2Aftercare (After-Treatment)
10/2005 - 02/2001
1Therapeutics
01/2007
1Drug Prescriptions
08/2006
1Vegetarian Diet (Vegetarianism)
10/2001